Hims & Hers offers a copycat of the blockbuster weight-loss drug at a fraction of the cost. But it might be a short-lived ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Genevieve Roberts thought weight-loss drugs were a miracle – until excruciating side-effects sent her straight back to a ...

New GLP-1RA weight loss drugs like Like Ozempic and Wegovy have become extremely popular in recent months but researchers ...

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Novo Nordisk NVO is scheduled to report fourth-quarter 2024 results on Feb. 5, 2025, before the opening bell. The Zacks ...

Robert F. Kennedy Jr., the nominee to lead the Department of Health and Human Services, made disputed claims before the ...

But the weight-loss market is far from typical ... “January is definitely a time when patients come in with new goals—many set over the holidays," said Dr. Disha Narang, director of obesity ...

But that will take political will and time ... "King Kong" of weight loss drugs by US expert Dr Julio Rosenstock after its effect size emerged , compared to the "gorilla" of Wegovy.